Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.
Researched for: PepTools vendor-neutral scientific reference catalog
Also known as: 9-fluoro-dihydro-7-hydroxymitragynine, 10-fluoro-dihydro-7-hydroxymitragynine, fluorinated dihydro-7-hydroxymitragynine, methyl (E)-2-((2S,3S,7aS,12aR,12bS)-3-ethyl-9-fluoro-7a-hydroxy-8-methoxy-1,2,3,4,6,7,7a,12,12a,12b-decahydroindolo[2,3-a]quinolizin-2-yl)-3-methoxyacrylate
MGM-16, also known as 9-fluoro-dihydro-7-hydroxymitragynine or 10-fluoro-dihydro-7-hydroxymitragynine, is a semisynthetic indole-alkaloid derivative related to mitragynine and 7-hydroxymitragynine. In preclinical studies, it showed high affinity for μ-opioid and δ-opioid receptors, full agonist activity in receptor-function assays, and antinociceptive or antiallodynic effects in mouse models. No human clinical efficacy or safety data were identified in the authoritative sources reviewed.
Source review pending. This descriptive profile is shown from the available source material as a best-effort educational reference. It has not passed the full verification bar and is not a dosing instruction, medical claim, or treatment recommendation.
Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.
Evidence is limited primarily to preclinical pharmacology and animal studies. The compound has no identified FDA-approved indication, and the reviewed DEA notice reported no approved or investigational new drug applications for MGM-16 in the United States as of January 20, 2026. Human pharmacokinetic, toxicology, dependence, and clinical safety data were not identified. Common reference sizes were not treated as an appropriate compound-level scientific catalog fact and were therefore left empty.
Supplementary research context only. Not medical advice or a treatment recommendation.
CAS RN 1158901-40-6; PubChem CID 168277847; molecular formula C23H31FN2O5; molecular weight 434.50 g/mol; InChIKey DKMVCOVCNPWGTO-CMWCKQEVSA-N; DOI 10.1124/jpet.113.208108; PMID 24345467
The 2014 primary study reported Ki values of 2.1 nM at the μ-opioid receptor and 7.0 nM at the δ-opioid receptor, with full agonist activity in G-protein and isolated-tissue assays. Oral administration produced antinociceptive and antiallodynic effects in mice. A DEA temporary scheduling order published August 26, 2026 identified MGM-16 as 9-fluoro-dihydro-7-hydroxymitragynine and placed it, including specified related forms, in Schedule I under the U.S. Controlled Substances Act for the stated temporary period. Regulatory status may vary by jurisdiction and may change.
Reflects published research. Educational reference — not a recommendation for use.
Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.
Published articles on this site that mention MGM-16 or one of its catalog aliases.
Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.